Home  |  Site Map  |  Contact Us  |  
Search

 

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. XenoPort is currently commercializing Horizant® (gabapentin enacarbil) Extended-Release Tablets, its first approved product in the United States, and developing a novel fumaric acid ester product candidate, XP23829, as a potential treatment for relapsing-remitting multiple sclerosis and/or psoriasis. Regnite is being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates also includes potential treatments for patients with spasticity related to spinal cord injury and Parkinson's disease.

For more information, please click here


For more information, please click here

Mon, 24 Feb 2014
XenoPort to Present at the Cowen and Company 34th Annual Health Care Conference

Thu, 20 Feb 2014
XenoPort Reports Fourth Quarter and Year-End 2013 Financial Results

 

2014 Cowen and Company 34th Annual Health Care Conference
Wednesday, March 5, 2014 5:00 PM ET

RBC Capital Markets' Global Healthcare Conference
February 25, 2014 2:35 PM ET

XenoPort is focused on development of product candidates for the potential treatment of central nervous system (CNS) disorders, including spasticity, Parkinson’s disease and relapsing-remitting multiple sclerosis.

Explore the XenoPort Pipeline >